2019.Apr.13
Clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study by Ministry of Health of the Russian Federation
Date of occurrence of the event: Apr 12, 2019 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A Cause of occurrence: Clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study by Ministry of Health of the Russian Federation. Countermeasures: N/A Any […]
This article is password protected.
To view the content, please enter your password in the field below